Ashvattha Therapeutics

Ashvattha Therapeutics

Pharmaceuticals, 1235 Radio Rd Ste 200, Redwood City, California, 94065, United States, 11-50 Employees

avttx.com

  • LinkedIn

Who is ASHVATTHA THERAPEUTICS

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusivel...

Read More

map
  • 1235 Radio Rd Ste 200, Redwood City, California, 94065, United States Headquarters: 1235 Radio Rd Ste 200, Redwood City, California, 94065, United States
  • 2015 Date Founded: 2015
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 4832

checked-icon Does something look wrong? Fix it. | View contact records from ASHVATTHA THERAPEUTICS

Ashvattha Therapeutics Org Chart and Mapping

Employees

Mark Feng

Director, Analytical Development

Siva Kambhampati

Principal Scientist, Research and Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Ashvattha Therapeutics

Answer: Ashvattha Therapeutics's headquarters are located at 1235 Radio Rd Ste 200, Redwood City, California, 94065, United States

Answer: Ashvattha Therapeutics's phone number is TRUE

Answer: Ashvattha Therapeutics's official website is https://avttx.com

Answer: Ashvattha Therapeutics's revenue is $1 Million to $5 Million

Answer: Ashvattha Therapeutics's SIC: 4832

Answer: Ashvattha Therapeutics has 11-50 employees

Answer: Ashvattha Therapeutics is in Pharmaceuticals

Answer: Ashvattha Therapeutics contact info: Phone number: TRUE Website: https://avttx.com

Answer: Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access